Novavax Stock News

Piper Sandler cut the price target on Bright Health Group, Inc. (NYSE: BHG) from $10 to $5. Bright Health shares rose 3.2% to $2.59 in pre-market trading. Needham cut C3.ai, Inc. (NYSE: AI) price

Novavax's vaccine story is just getting started.

Novavax''s vaccine story is just getting started.

GAITHERSBURG, Md., March 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in Cowen''s 42nd Annual Healthcare…

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The best chance for profits with NVAX stock is with the international market. But Russia''s invasion of Ukraine could put Novavax''s strategy at risk. The post Russia’s Aggression Could Put a Damper on Novavax Global Vax Deployment appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Novavax executives are talking about making big bucks this year.

Novavax executives are talking about making big bucks this year.

Novavax, Inc. (NASDAQ: NVAX) Q4 2021 earnings call dated Feb. 28, 2022 Corporate Participants: Silvia Taylor — Senior Vice President of Global Corporate Affairs and Investor Relations Stanley C. Erck — President and Chief […] The post Novavax, Inc. (NVAX) Q4 2021 Earnings Call Transcript first appeared on AlphaStreet .

Novavax, the jab popular with anti-vaxxers, has been approved for use as a booster in Australia by ATAGI - with more than 25,000 doses already being administered.

Novavax is set to be approved as a Covid booster shot for Aussies aged 18 years and over.

After a busy final quarter of 2021, Novavax''s CEO said he expects the Maryland company''s "momentum will only accelerate" this year.

Investors have a reason to be optimistic about Novavax's fortunes -- at least over the near term.

Investors have a reason to be optimistic about Novavax''s fortunes -- at least over the near term.

Novavax <> is set to close higher on Tuesday for the fourth straight session as Wall Street cheers the outlook for its COVID-19 vaccine despite lower-than-expected financials…

Investors might have been disappointed with Novavax’s (NVAX) latest quarterly results, but Jefferies analyst Roger Song thinks a “transformational year” could be in…